Key result
Octreotide increases supine BP and extends tilt-test duration ~28% without altering HR or norepinephrine.
Why the study?
Does octreotide improve blood pressure and orthostatic tolerance in patients with orthostatic hypotension due to multiple system atrophy?
RCT (n=9)
randomly controlled
Does octreotide improve blood pressure and orthostatic tolerance in patients with orthostatic hypotension due to multiple system atrophy?
Octreotide administration improves supine blood pressure and tilt-test duration in patients with orthostatic hypotension secondary to multiple system atrophy.
Answers are grounded in this paper and cite their sources.
Octreotide may improve orthostatic tolerance in MSA; extends small-RCT evidence for somatostatin analogs in neurogenic hypotension.
In nine patients with orthostatic hypotension due to multiple system atrophy, the effects of octreotide (100 micrograms s.c.), a somatostatin analogue, on blood pressure (BP), heart rate (HR), and norepinephrine (NE) plasma levels after 60 degrees head up tilt test were evaluated by a randomly controlled study. Octreotide increased supine BP, tilt-test duration (+28%), and delay to obtain minimal BP during the 60 degrees head up tilt (+50%). Octreotide changed neither HR nor NE plasma levels.
No takes yet. Share an insight, caveat, or question.
Bordet et al. (1995) conducted an RCT in orthostatic hypotension due to multiple system atrophy (n=9). Octreotide was evaluated on Blood pressure, heart rate, and norepinephrine plasma levels after 60 degrees head up tilt test. Octreotide increased supine BP, tilt-test duration, and delay to minimal BP during a 60-degree head-up tilt test, without changing HR or norepinephrine levels.
Synapse has enriched 10 related papers. Consider them for comparative context: